Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM)

Inclusion Criteria

• •\> 18 years old
• •PCa, treated with curative intent (radical prostatectomy, primary radiotherapy, or a combination of both) and oligorecurrent/oligopersistent metastasis (1 - 5 lesions) on imaging (PSMA-PET, CT, MRI).
• •Recurrence or progression of metastases on imaging (PSMA-PET, CT, MRI) that cannot be treated with SBRT, either due to a history of previous high-dose radiotherapy with dose constraints, because SBRT is technically unfeasible or unsafe for the specific lesions, or because the patient refuses to undergo SBRT.
• •PSMA-positive lesion
• •Lesions up to 4 cm that are suitable and safe for TA with an anticipated high rate of technical success
• •'Eastern Cooperative Oncology Group' (ECOG) performance status of 2 or less.
• •Patients can be androgen sensitive (mHSPC) or castration resistant (mCRPC).
• •All patients will be discussed at the Multidisciplinary Tumor Board.